Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs

Gene Therapy

Volumn 6, Issue 12, 1999, Pages 1972-1981

  Chen, C H ^a,b   Ji, H ^a   Suh, K W ^a   Choti, M A ^a   Pardoll, D M ^a   Wu, T C ^a,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Antitumor; DNA vaccine; E7; Human papillomaviruses; LAMP 1; Metastasis

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; MEMBRANE PROTEIN; ONCOPROTEIN; PLASMID VECTOR; VIRUS ANTIBODY; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE GUN; HUMORAL IMMUNITY; IMMUNOTHERAPY; LIVER METASTASIS; LUNG METASTASIS; LYSOSOME; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; STEM CELL; TUMOR IMMUNITY; TUMOR REGRESSION; VIRUS GENE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD; BIOLISTICS; GENETIC VECTORS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR VIRUS INFECTIONS; VACCINES, DNA;

ANIMALIA; DNA VIRUSES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MURINAE; PAPILLOMAVIRUS;

EID: 0033380078     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301067     Document Type: Article

References (42)

1. Chen CH, Wu TC. Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 1998; 5: 231-252.
2. Sznol M, Holmlund J. Antigen-specific agents in develoment (review). Semin Oncol 1997; 24: 173-186.
3. Jaffee EM, Pardoll DM. Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods 1997; 12: 143-153.
4. Pardoll DM, Beckerleg AM. Exposing the immunology of naked DNA vaccines (review). Immunity 1995; 3: 165-169.
5. Donnelly JJ, Ulmer JB, Liu MA. DNA vaccines (review). Life Sci 1997; 60: 163-172.
6. Robinson HL, Torres CA. DNA vaccines. Semin Immunol 1997; 9: 271-283.
7. Lin K-Y et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-26.
8. Ji H et al. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 1998; 78: 41-45.
9. Hanke T et al. Enhancement of MHC class-I-restricted peptide-specific T cell induction by a DNA prirne/MVA boost vaccination regime. Vaccine 1998; 16: 439-445.
10. Henriksen E. The lymphatic spread of carcinoma of the cervix and of the body of the uterus: a study of 420 necropsies. Am J Obstet Gynecol 1949; 58: 924-942.
11. Gilboa E. Murine models for cancer immunotherapy using cytokine gene modified tumor vaccines. In: Forni G, Foa R, Santoni A, Frati L (eds). Cytokine-induced Tumor Immunogeneity. Academic Press: London, 1994, pp 130-143.
12. Melief CJ, Kast WM. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 1995; 145: 167-177.
13. Murali-Krishna K et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998; 8: 177-187.
14. Conry RM et al. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Therapy 1995; 2: 59-65.
15. Syrergelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nature Med 1996; 2: 1038-1041.
16. Bright RK et al. Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen. Cancer Res 1996; 56: 1126-1130.
17. Schirmbeck R, Bohm W, Reimann J. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors. J Immunol 1996; 157: 3550-3558.
18. Rosato A et al. CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. Hum Gene Ther 1997; 8: 1451-1458.
19. Geissler M et al. Genetic immunization with the free human chorionic gonadotropin beta subunit elicits cytotoxic T lymphocyte responses and protects against tumor formation in mice. Lab Invest 1997; 76: 859-871.
20. Schreurs MW et al. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lyphocyte-mediated tumor protection. Cancer Res 1998; 58: 2509-2514.
21. Chen Y et al. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res 1998; 58: 1965-1971.
22. Iwasaki A, Barber BH. Induction by DNA immunization of a protective antitumor cytotoxic T lymphocyte response against a minimal-epitope-expressing tumor. Cancer Immunol Immunother 1998; 45: 273-279.
23. Ciernik IF, Berzofsky JA, Carbone DP. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 1996; 156: 2369-2375.
24. Irvine KR et al. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996; 156: 238-245.
25. Ross HM et al. Priming for T-cell-mediated rejection of established rumors by cutaneous DNA immunization. Clin Cancer Res 1997; 3: 2191-2196.
26. Ulmer JB et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-1749.
27. Sparwasser T et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998; 28: 2045-2054.
28. Cohen AD, Boyer JD, Weiner DB. Modulating the immune response to genetic immunization. FASEB J 1998; 12: 1611-1626.
29. Condon C et al. DNA-based immunization by in vivo transfection of dendritic cells. Nature Med 1996; 2: 1122-1128.
30. Iwasaki A et al. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J Immunol 1997; 159: 11-14.
31. Porgador A et al. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ cells after gene gun immunization. J Exp Med 1998; 188: 1075-1082.
32. Klinman DM et al. Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory. J Immunol 1998; 160: 2388-2392.
33. Wu TC et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 1995; 92: 11671-11675.
34. Ruff AL et al. The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway. J Biol Chem 1997; 272: 8671-8678.
35. Boyle JS, Koniaras C, Lew AM. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int Immunol 1997; 9: 1897-1906.
36. Choi AH et al. Particle-bombardment-mediated DNA vaccination with rota virus VP4 or VP7 induces high levels of serum rotavirus IgG but fails to protect mice against challenge. Virology 1998; 250: 230-240.
37. Akbari O et al. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 1999; 189: 169-178.
38. Sigal LJ et al. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999; 398: 78-80.
39. + T cell help. J Exp Med 1997; 186: 65-70.
40. Feltkamp MC et al. Vaccination with cytotoxic T lymphcoyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-2249.
41. Miyahira Y et al. Quantification of antigen specific CD8+ T cells using an ELlSPOT assay. J Immunol Meth 1995; 181: 45-54.
42. McCutcheon M et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Meth 1997; 210: 149-166.